Dova Pharmaceuticals’ New Drug Application (NDA) for avatrombopag has been granted Priority Review by the United States Food and Drug Administration. The drug is specifically intended for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.    The submission is based on two identically-designed Phase 3 clinical trials, ADAPT 1 and ADAPT 2, in which avatrombopag met all primary and secondary endpoints with high statistical sign...